Section 280E in Cannabis M&A: Tax Structuring, Deal Modeling, and the Rescheduling Contingency

Section 280E of the Internal Revenue Code imposes a tax burden on cannabis businesses that has no parallel in any other domestic industry. By prohibiting deductions and credits for any trade or business consisting of trafficking in Schedule I or II controlled substances, 280E forces cannabis operators to pay federal income tax on gross profit rather than net income. In a business with meaningful selling, general, and administrative expenses, the effective federal tax rate can reach 70 percent or higher of actual economic income. In cannabis M&A, this creates a structuring and valuation environment fundamentally different from any other transaction type.

The implications extend across every aspect of deal analysis. EBITDA as reported by cannabis targets does not represent taxable income in any conventional sense. Transaction costs that would be deductible in most acquisitions are disallowed. Net operating losses generated by cannabis operations interact with 280E in ways that reduce their utility. Basis step-ups from asset purchase structures provide diminished benefit when the deductions generated by depreciation are themselves subject to 280E disallowance. And the pending rescheduling of cannabis under the Controlled Substances Act introduces a contingent future event that currently sits as an unpriced variable in most cannabis deal models.

This sub-article is part of the Cannabis M&A: Navigating State Licensing, Section 280E, and Federal Illegality in Deal Structuring guide. It addresses Section 280E from first principles through deal-level application: statutory mechanics, COGS as the surviving deduction path, Section 471(c) interplay, cultivation and dispensary COGS differences, IRS enforcement history, holding company structures, deal modeling, transaction cost deductibility, NOL interaction, basis step-up limitations, and rescheduling contingency planning. Nothing in this article constitutes legal or tax advice for any specific transaction.

Why 280E Dwarfs Every Other Tax Consideration in Cannabis M&A

In a conventional M&A transaction, federal income tax considerations affect the buyer's effective cost of ownership and the seller's after-tax proceeds, but the underlying business is subject to a tax system that broadly mirrors economic reality. Revenue less ordinary and necessary business expenses equals taxable income. Cannabis does not operate under that system. Section 280E strips out the ordinary expense deductions that define taxable income in every other industry, leaving a tax base that bears little relationship to economic profit.

The practical consequence is that a cannabis business with strong gross margins but significant operating expenses may generate modest or negative economic profit while simultaneously incurring substantial federal income tax liability. A dispensary earning $5 million in gross profit on $10 million of revenue, with $3.5 million in operating expenses below the COGS line, generates $1.5 million of economic income but pays federal tax on a 280E-adjusted taxable income significantly higher than that because most of the $3.5 million in operating expenses is disallowed. The gap between economic income and taxable income is the defining financial characteristic of cannabis businesses under current law.

For acquirers, this means that the price paid for a cannabis business cannot be justified on conventional after-tax return metrics without explicit modeling of the 280E tax layer. For sellers, it means that transaction structuring has material consequences for how much of the deal consideration they retain after tax. For both parties, 280E is not a secondary tax consideration to be addressed in diligence. It is the primary economic variable that determines whether a cannabis transaction is financially viable on the terms proposed, and it must be centered in deal modeling from the earliest stages of negotiation.

Statutory Language and What It Prohibits

Section 280E provides, in full, that no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted. Congress enacted this provision in 1982 in response to a Tax Court decision in which a drug dealer successfully claimed ordinary business deductions for his trafficking operation because nothing in the then-existing Code expressly prohibited it.

The statutory language reaches further than it might initially appear. The phrase "trade or business that consists of trafficking" has been interpreted by the IRS and courts to apply to any business whose principal activity is cannabis sales, even if the business also conducts ancillary activities. A vertically integrated cannabis company that cultivates, processes, and retails cannabis cannot segregate the retail trafficking from the cultivation and claim that cultivation is a separate non-trafficking business for 280E purposes, because the overall enterprise consists of trafficking. The critical question is not whether the business conducts some non-cannabis activities, but whether the business, considered as a whole, constitutes trafficking in a Schedule I substance.

The disallowance covers both deductions and credits, meaning that research and development credits, energy investment credits, and other business tax credits are also eliminated for cannabis trafficking businesses. The disallowance applies to expenses incurred in carrying on the trade or business regardless of whether those expenses would otherwise be deductible under any provision of the Code: rent, wages, insurance, professional fees, marketing, travel, and every other ordinary business expense is disallowed at the federal level. State income tax treatment varies based on state conformity to the federal code, and several cannabis-legal states have decoupled from 280E for state income tax purposes.

COGS as the Surviving Deduction Path

The only meaningful tax relief available to cannabis businesses under current federal law runs through cost of goods sold. COGS is not a deduction in the technical sense: it is a reduction of gross receipts in the computation of gross income. Section 280E disallows deductions and credits, but the computation of gross income, including the subtraction of inventory cost through COGS, occurs at a prior step in the income calculation. The Supreme Court confirmed this structural distinction in a line of authority establishing that gross income means gross receipts less cost of goods, not gross receipts alone. Because 280E disallows deductions but does not reach the COGS offset to gross receipts, COGS represents the one pathway through which cannabis businesses can reduce their federal taxable income.

The strategic implication is direct: every dollar that can be legitimately capitalized into inventory cost and recovered through COGS reduces taxable income in a 280E environment on a dollar-for-dollar basis. Every dollar that cannot be capitalized and must be treated as a period expense is permanently lost for federal tax purposes. This inversion of normal accounting economics, where accelerating expense recognition is generally tax-preferred, means that cannabis businesses should maximize capitalization of costs into inventory rather than expensing them immediately. The applicable rules for determining which costs may be capitalized into COGS are the standard inventory accounting rules under Section 471, as modified post-TCJA by Section 471(c) for eligible small businesses.

Acquirers conducting diligence on cannabis targets should analyze whether the target has been maximizing its COGS capitalization under applicable accounting rules or leaving COGS on the table by expensing costs that could have been capitalized. Targets that have underutilized COGS capitalization represent a planning opportunity that the acquirer can implement post-closing. Conversely, targets that have been aggressive in COGS capitalization may have taken positions that the IRS could challenge, creating a contingent tax liability that must be evaluated and priced into the transaction.

Section 471(c) and Small Business Inventory Rules

The Tax Cuts and Jobs Act of 2017 added Section 471(c) to the Internal Revenue Code, creating a simplified inventory accounting method for taxpayers with average annual gross receipts of $30 million or less over the three prior tax years. Under Section 471(c), a qualifying small business may account for inventories using its method of accounting reflected in an applicable financial statement, or, if no applicable financial statement exists, the books and records of the taxpayer prepared in accordance with its accounting procedures. This provision has significant implications for cannabis businesses because it potentially allows broader cost capitalization than the traditional Treasury Regulation 1.471-11 full absorption method.

Under full absorption costing under Regulation 1.471-11, the costs that must or may be capitalized into inventory are defined by specific categories in the regulation, including direct material, direct labor, and certain categories of indirect production costs. Administrative costs unrelated to production, selling expenses, and certain overhead items are categorized as period costs that must be expensed rather than capitalized. Section 471(c) opens the possibility that a cannabis business using GAAP financial statements, which require capitalization of production-related overhead under ASC 330, can capitalize a broader range of costs than the Regulation 1.471-11 categories permit, with the result that COGS is larger and the 280E-taxable gross profit is correspondingly lower.

The IRS issued Notice 2020-59 confirming that qualifying small businesses may use the Section 471(c) method, and the Treasury finalized regulations in 2021 addressing implementation details. Cannabis businesses that qualify under the $30 million gross receipts threshold and have not yet adopted the Section 471(c) method should evaluate whether doing so would expand their COGS and reduce their 280E-taxable income. In cannabis M&A, the acquirer should determine at diligence whether the target qualifies for 471(c), whether it has elected the method, and if not, whether the election could be made post-closing. The election requires an accounting method change that may require IRS consent, and timing the election relative to the transaction close should be addressed in deal planning.

Cultivation vs. Dispensary COGS Mechanics

The costs that can be captured in COGS differ substantially between cannabis cultivation operations and cannabis retail dispensaries, and vertically integrated operators must maintain clear cost flow documentation to support COGS allocation across the value chain. Understanding these differences is essential to evaluating a target's tax position and identifying post-acquisition planning opportunities.

For cannabis cultivators, COGS reflects the cost of producing cannabis plants through harvest. Capitalizable production costs include seeds and clones, growing media and nutrients, direct labor for cultivation staff, utilities consumed in grow facilities, depreciation on cultivation equipment (lights, HVAC, irrigation systems), rent attributable to cultivation space, and quality control costs directly tied to production. Post-harvest processing costs, including drying, curing, trimming, and packaging, are also capitalizable as additional processing steps before the product enters finished goods inventory. The total of these costs, divided by the quantity of cannabis produced, establishes the cost per unit that flows into COGS when inventory is sold. Cultivators with high production cost structures, particularly those operating indoor facilities with significant utility and labor costs, can achieve relatively high COGS as a percentage of revenue, which provides meaningful 280E relief.

Retail dispensaries that purchase finished cannabis products from third-party cultivators or processors have a simpler COGS structure: the purchase price of the cannabis products acquired for resale, plus any additional costs of preparing the products for sale, such as repackaging or labeling costs that are incurred before the product is sold to the customer. Dispensaries cannot capitalize their retail overhead, employee compensation for budtenders, or occupancy costs for retail space as COGS. This limitation means that pure retail operators generally have a lower COGS-to-revenue ratio than vertically integrated operators, and therefore a higher 280E-taxable gross income as a percentage of revenue. Vertically integrated operators that cultivate and retail their own product can capture a full stack of production costs in COGS, producing a structurally more favorable 280E position than a pure retailer sourcing from third parties.

Enforcement History and Taxpayer Defeats

The IRS has actively enforced Section 280E against cannabis businesses, and the Tax Court has uniformly upheld the statute's constitutionality and application against challenges. The enforcement record establishes several principles that now govern cannabis tax planning and that acquirers must understand when evaluating a target's historical tax compliance.

Harborside Health Center v. Commissioner is the most prominent 280E enforcement case in the cannabis context. The IRS assessed substantial additional tax liabilities against Harborside, a California dispensary, arising from its treatment of expenses as deductible business costs. The Tax Court ruled for the IRS on the core 280E application but also addressed Harborside's argument that it operated a separate caregiving and wellness business alongside its cannabis sales, which it contended was a distinct trade or business not subject to 280E. The court rejected the separate trade or business argument because Harborside's wellness services were not meaningfully separable from its cannabis operation: the caregiving activities were conducted in the same locations, marketed to the same customers, and staffed by the same employees as the cannabis sales. The lesson is that a cannabis business cannot escape 280E by pointing to ancillary services that are integrated into the primary cannabis operation.

CHAMP v. Commissioner and Olive v. Commissioner further refined the standards for when a separate trade or business exists outside the cannabis trafficking business for 280E purposes. Both cases confirmed that the inquiry is fact-intensive and turns on whether the non-cannabis activities could exist and function independently of the cannabis operation, whether they have their own distinct customer relationships and revenue streams, and whether they are operated with separate accounting, staffing, and management. Acquirers should review the target's history of taking separate trade or business positions in its returns and whether those positions are supported by the operational facts documented in IRS-ready form.

Holding Company and Non-Plant-Touching Carve-Outs

One of the most actively pursued structural strategies in cannabis M&A is the separation of plant-touching operations from management, intellectual property, real estate, and other functions into entities that do not themselves traffic in cannabis. If correctly structured and operated, these non-plant-touching entities are not subject to Section 280E, and the income and expenses of those entities are taxed under normal Section 162 rules. The holding company structure attempts to shift as much economic activity as possible into the non-280E entity, reducing the proportion of the enterprise's overall income that is subject to the disallowance.

Common implementations include a parent holding company that licenses intellectual property, including brand assets and proprietary cultivation methods, to cannabis-licensed operating subsidiaries under arm's-length royalty agreements. The royalty income flows to the holding company free from 280E. Similarly, a real estate holding entity that owns the properties used by cannabis operations can charge rent to the licensed operator, with the rental income taxed normally in the holding entity. Management companies that provide back-office functions, compliance services, and human resources to cannabis licensees under management services agreements can receive management fees taxed outside 280E if the management company does not itself engage in cannabis sales or distribution.

The IRS has scrutinized these structures, and their success depends on genuine operational separation. Intercompany contracts must be at fair market value: below-market royalties that shift income to the holding company without economic justification, or above-market management fees that extract income from the cannabis entity and deposit it in a non-280E entity, are vulnerable to IRS recharacterization. The non-plant-touching entities must have genuine business purpose and independent function. If the holding company's only purpose is to receive payments from the cannabis subsidiary and its activities would collapse without the cannabis subsidiary, the IRS will argue that the holding company's income is attributable to the cannabis trafficking business and should be subject to 280E as part of an integrated enterprise. Acquirers evaluating targets using these structures should verify that the intercompany arrangements reflect market terms and are operationally substantiated.

Deal Modeling: Pre-Tax vs. Post-Tax EBITDA

Cannabis deal modeling requires an additional layer of analysis not present in conventional M&A: the computation of 280E-adjusted taxable income and the resulting cash tax burden on top of the EBITDA-based valuation framework. In most industries, EBITDA is used as a proxy for pre-tax cash flow because the step from EBITDA to taxable income, while not trivial, involves predictable adjustments. In cannabis, the step from reported EBITDA to 280E-adjusted taxable income is not predictable from financial statements alone and can be dramatic.

A cannabis target reporting $4 million of EBITDA may have 280E-adjusted taxable income of $6 million or more if $2 million of expenses reflected in the EBITDA computation are below-the-COGS-line operating costs that 280E disallows. The federal tax on $6 million of taxable income at the 21 percent corporate rate is $1.26 million, while the tax on the conventionally computed $4 million, if it were taxable income, would be $840,000. The difference is $420,000 annually, and capitalized over a five-year deal horizon at a 10x EBITDA multiple, that difference represents a material negative adjustment to enterprise value that must be reflected in the purchase price.

Buyers should build a 280E tax model that begins with the target's historical income statement, identifies all expenses below the COGS line that are subject to 280E disallowance, and computes the tax on the resulting adjusted taxable income. The model should then project forward using the buyer's post-acquisition operating plan, including any planned structural changes (such as implementing a 471(c) election or restructuring intercompany arrangements) that would alter the 280E-adjusted taxable income. The post-transaction cash tax burden, expressed as a percentage of EBITDA, should be compared to the equivalent burden in comparable non-cannabis transactions to quantify the 280E discount that should be reflected in the purchase price. Sellers who understand this analysis can engage with buyers on valuation with greater credibility than those who resist 280E adjustments and insist on EBITDA multiples without tax adjustment.

Transaction Cost Deductibility and Capitalization

The deductibility of transaction costs in cannabis M&A is constrained by the interaction of 280E with the standard rules governing the treatment of deal costs under Sections 162, 263, and the INDOPCO regulations. Under normal tax rules, certain transaction costs incurred by a seller in connection with a business sale are deductible as ordinary business expenses, while other costs must be capitalized and either amortized over the applicable period or treated as a reduction of the seller's amount realized. The buyer generally capitalizes costs into the basis of acquired assets. In cannabis, the analysis is further complicated by 280E's effect on the seller's ability to deduct transaction costs.

For the seller, legal fees, financial advisory fees, and accounting fees incurred in connection with the sale may be deductible under Section 162 if they are ordinary and necessary business expenses in the year incurred. However, if the seller's business is a cannabis trafficking operation subject to 280E, those deductions are disallowed at the federal level regardless of whether they would otherwise qualify under Section 162. The seller therefore bears the full economic cost of transaction advisory fees without a tax deduction to partially offset that cost, increasing the effective cost of the transaction from the seller's perspective. This is a negotiating point in deal economics: sellers in cannabis transactions face higher effective transaction costs than sellers in non-cannabis transactions, and the allocation of deal costs between buyer and seller may reflect that asymmetry.

For the buyer, transaction costs that must be capitalized under the INDOPCO regulations are added to the basis of the acquired assets and recovered through depreciation or amortization over the applicable period. This is the standard treatment for most acquisition costs and is not altered by 280E, because the buyer's obligation to capitalize is a function of the nature of the costs, not the nature of the acquired business. The complication arises post-acquisition: depreciation deductions on capitalized transaction costs attributable to assets used in the cannabis trafficking business are themselves subject to 280E disallowance. The buyer capitalizes the costs correctly but may be unable to deduct the resulting depreciation if the assets are used in the trafficking business.

NOL Availability and 280E Interaction

Net operating losses generated by cannabis operations interact with Section 280E in ways that substantially reduce their utility relative to NOLs generated by non-cannabis businesses. Under post-TCJA law, NOLs arising in taxable years beginning after December 31, 2017 can be carried forward indefinitely but are limited to 80 percent of taxable income in the year of use, with no carryback (except for a temporary carryback provision for 2018 through 2020 NOLs that has since expired). For cannabis businesses, these rules apply against the 280E-adjusted taxable income base, not the economic income base.

A cannabis business that generates an economic loss in a given year because operating expenses exceed gross profit may nonetheless have 280E-adjusted taxable income because many of those operating expenses are disallowed. If the company's COGS is less than its revenue, it has positive gross income for federal tax purposes even if it has an economic loss when period expenses are considered. In that scenario, no NOL is generated despite the economic loss: the company has taxable income and owes federal tax even though it lost money. Conversely, a cannabis business may generate an NOL only in the rare circumstance where its COGS exceeds its revenue, which typically signals a severely distressed operation rather than a normal business cycle event.

For acquirers evaluating targets with existing NOL carryforwards, the analysis must account for this dynamic. A cannabis NOL reflected on the target's returns may have been generated in a period where the operation was genuinely non-economic, not simply in a period of temporary underperformance that recovered, and may reflect a more severe operational history than a comparable NOL at a non-cannabis business would suggest. NOL carryforwards at cannabis businesses are also subject to Section 382 limitations if there has been an ownership change, which the acquisition itself will trigger. The interaction of Section 382 limitations with the already-constrained 280E taxable income base may render the acquired NOLs of limited value for planning purposes, and buyers should not assign significant value to cannabis NOL carryforwards without a careful analysis of both the 382 limitations and the expected post-acquisition 280E-adjusted taxable income against which those NOLs could be used.

Basis Step-Up Value Limitations Under 280E

Asset purchase structures, and stock purchase structures with a Section 338(h)(10) election, allow the buyer to step up the tax basis of the target's assets to their fair market value at closing. This step-up generates future depreciation and amortization deductions that reduce the buyer's taxable income over the applicable recovery periods. In non-cannabis M&A, this basis step-up is one of the primary tax benefits of the asset purchase structure and frequently justifies paying a premium over the stock purchase price. In cannabis M&A, the value of the basis step-up is substantially reduced by 280E because the depreciation and amortization deductions generated by the stepped-up basis are subject to the same disallowance that applies to all other deductions in a cannabis trafficking business.

The exception to this conclusion involves assets whose depreciation can be capitalized into inventory cost and recovered through COGS. Cultivation equipment, processing machinery, and other production assets that contribute to cannabis product manufacturing may have their depreciation treated as a production cost capitalized into inventory under the applicable inventory accounting rules. To the extent depreciation flows through COGS rather than appearing as a period expense, it is not subject to 280E disallowance and is recoverable as an offset to gross receipts. For these production assets, a basis step-up retains meaningful value: higher basis generates more depreciation, which is capitalized into inventory, producing higher COGS, which reduces 280E-taxable gross income.

For non-production assets, including retail fixtures, administrative equipment, leasehold improvements in non-production spaces, and intangible assets such as goodwill and customer relationships amortized under Section 197, the depreciation and amortization generated by a basis step-up is a period expense that 280E disallows. A buyer paying a premium for an asset purchase structure that generates a $10 million step-up in 197 intangibles will receive $1.5 million of annual amortization over 15 years, but none of that amortization will be deductible if the buyer's cannabis business is subject to 280E. The premium paid for the asset structure must be evaluated against the realistic benefit of the step-up after accounting for the 280E disallowance of the resulting deductions.

Planning for Prospective Rescheduling and Refund Positioning

The DEA's initiation of rulemaking to reschedule cannabis from Schedule I to Schedule III, following the Department of Health and Human Services recommendation, has introduced a new planning dimension in cannabis M&A. If rescheduling is finalized, Section 280E would no longer apply to cannabis businesses because the statute's disallowance is expressly limited to Schedule I and II substances. The effective date and the mechanics of the transition from 280E to normal taxation are questions that existing guidance does not resolve, and the rescheduling process faces continuing legal and regulatory uncertainty that prevents any confident timeline prediction.

The prospective elimination of 280E upon rescheduling would immediately allow cannabis businesses to deduct all ordinary and necessary business expenses under Section 162, converting their taxable income computation from a gross profit basis to a net income basis. The economic effect on profitable cannabis businesses would be an immediate and substantial reduction in effective federal tax rates, with the magnitude depending on the ratio of below-the-COGS-line operating expenses to gross profit. This prospective benefit is a legitimate component of cannabis enterprise valuation and is beginning to appear in deal model discussions as a probability-weighted upside case, though the pricing of that contingency remains highly deal-specific.

For prior tax years, the refund positioning strategy requires advance record-keeping. Rescheduling operates prospectively: deductions disallowed in prior years under 280E cannot automatically be recovered simply because the law changes. However, if rescheduling creates a legal basis to file amended returns claiming refunds for prior-year taxes paid on income that would have been offset by currently disallowed expenses, those claims will be available only for tax years within the applicable statute of limitations. Operators should maintain year-by-year schedules of all expenses disallowed under 280E, with sufficient documentation to support amended return filings under any allowable legal theory, so that if rescheduling occurs, those claims can be filed without delay. In M&A transactions, the purchase agreement should address the allocation of any refund claims between buyer and seller, and the seller representations should cover the accuracy of the target's historical 280E compliance positions.

Frequently Asked Questions